Metagenomi Therapeutics, Inc. (MGX)
1.02
+0.02
(+2.00%)
USD |
NASDAQ |
Oct 12, 16:00
1.02
0.00 (0.00%)
After-Hours: 20:00
Metagenomi Therapeutics Enterprise Value : -44.41M for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | -44.41M |
| October 09, 2026 | -45.17M |
| October 08, 2026 | -45.42M |
| October 07, 2026 | -45.74M |
| October 06, 2026 | -44.03M |
| October 05, 2026 | -43.66M |
| October 02, 2026 | -44.41M |
| October 01, 2026 | -41.20M |
| September 30, 2026 | -42.90M |
| September 29, 2026 | -40.26M |
| September 28, 2026 | -39.88M |
| September 25, 2026 | -39.50M |
| September 24, 2026 | -39.50M |
| September 23, 2026 | -40.26M |
| September 22, 2026 | -39.88M |
| September 21, 2026 | -40.63M |
| September 18, 2026 | -41.39M |
| September 17, 2026 | -40.26M |
| September 16, 2026 | -39.50M |
| September 15, 2026 | -39.12M |
| September 14, 2026 | -37.99M |
| September 11, 2026 | -39.12M |
| September 10, 2026 | -39.12M |
| September 09, 2026 | -39.50M |
| September 08, 2026 | -39.12M |
| Date | Value |
|---|---|
| September 04, 2026 | -38.74M |
| September 03, 2026 | -39.12M |
| September 02, 2026 | -39.12M |
| September 01, 2026 | -38.74M |
| August 31, 2026 | -38.37M |
| August 28, 2026 | -37.99M |
| August 27, 2026 | -37.23M |
| August 26, 2026 | -36.86M |
| August 25, 2026 | -37.23M |
| August 24, 2026 | -37.23M |
| August 21, 2026 | -36.48M |
| August 20, 2026 | -37.61M |
| August 19, 2026 | -36.10M |
| August 18, 2026 | -37.23M |
| August 17, 2026 | -36.86M |
| August 14, 2026 | -36.48M |
| August 13, 2026 | -36.48M |
| August 12, 2026 | -36.86M |
| August 11, 2026 | -37.23M |
| August 10, 2026 | -36.48M |
| August 07, 2026 | -36.48M |
| August 06, 2026 | -36.10M |
| August 05, 2026 | -37.04M |
| August 04, 2026 | -37.23M |
| August 03, 2026 | -37.23M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.346B |
| Oncolytics Biotech, Inc. | 55.32M |
| Sangamo Therapeutics, Inc. | 53.89M |
| Sarepta Therapeutics, Inc. | 2.099B |
| Anixa Biosciences, Inc. | 83.26M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.48M |
| Revenue (Quarterly) | -0.257M |
| Total Expenses (Quarterly) | 27.22M |
| EPS Diluted (Quarterly) | -0.7298 |
| Earnings Yield | -243.9% |
| Normalized Earnings Yield | -243.94 |